Related Experiment Video
Updated: May 12, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
MUC1 as a potential target in anticancer therapies
Krishna Pillai1, Mohammad H Pourgholami, Terence C Chua
1Department of Surgery, University of New South Wales, St. George Hospital, Sydney, NSW, Australia.
American Journal of Clinical Oncology
|April 24, 2013
Summary
Mucin 1 (MUC1) is a glycoprotein overexpressed in cancers, promoting tumor growth and metastasis. Current therapies targeting MUC1, including antibodies and vaccines, are under development but require further evaluation before clinical application.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Mucin 1 (MUC1) is a glycoprotein overexpressed in various tumor cells, contributing to cancer invasiveness, metastasis, and survival.
- In normal cells, MUC1 provides protection and lubrication, but its aberrant expression in cancer disrupts these functions.
- MUC1 exists as two heterodimers, MUC1-N and MUC1-C, with distinct roles in cancer progression.
Purpose of the Study:
- To review the structure and function of MUC1 in normal and cancerous cells.
- To explore current and emerging therapeutic strategies targeting MUC1.
- To assess the clinical applicability and limitations of MUC1-targeted therapies.
Main Methods:
- Review of scientific literature on MUC1 structure, function, and overexpression in cancer.
- Analysis of different therapeutic approaches including monoclonal antibodies (MAb), vaccines, and aptamers.
- Evaluation of the mechanisms of action and developmental status of MUC1-targeted therapies.
Main Results:
- MUC1-N is heavily glycosylated and targeted by some MAb and vaccines, with limited success.
- MUC1-C, with its cytoplasmic domain (MUC1-C/CD), plays a crucial role in tumor growth via phosphorylation.
- Newer therapies are focusing on MUC1-C, utilizing antibodies, vaccines, and aptamers to block critical signaling pathways or deliver cytotoxic drugs.
Conclusions:
- MUC1 is a promising target for cancer therapy due to its overexpression and role in tumor progression.
- While various MUC1-targeting therapies have been developed, none have reached clinical application yet.
- Further refinement and rigorous evaluation are necessary to advance MUC1-targeted therapies towards successful clinical use.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...